A federal appeals court has issued a temporary block on the rule allowing the distribution of the abortion drug mifepristone via mail. This decision significantly restricts access to the medication nationwide, impacting individuals particularly in states that have enacted abortion bans. The New Orleans-based 5th U.S. Circuit Court of Appeals is now requiring that the pill be distributed only in person at clinics. This ruling marks the first significant curtailment of mifepristone access stemming from lawsuits challenging its approval and subsequent accessibility regulations.
Nationwide Access Restricted
The appeals court's order reinstates an earlier requirement for in-person dispensing of mifepristone, a move that directly undermines access to medication abortion, which has become increasingly widespread. Medication abortion now accounts for roughly two-thirds of all abortions performed in the United States. The ruling stems from a legal challenge filed by Louisiana's attorney general and an individual who alleged coercion into taking abortion pills. They sought to roll back FDA regulations to a point where the pills could only be prescribed and dispensed in person.
Read More: Myles Gray death inquiry delayed again until fall
Legal Challenge and FDA Review
The 5th Circuit Court of Appeals indicated that Louisiana is likely to succeed in its legal challenge against the Food and Drug Administration's rules. The judges noted that the FDA "could not say when that review might be complete and admitted it was still collecting data" regarding the drug's safety. This uncertainty about the review's timeline and data collection was a factor in the court's decision to impose the temporary restriction.
The legal battle has been ongoing, with previous challenges to mifepristone's approval in 2000 and subsequent rules easing its acquisition. A district court in Louisiana had previously denied a similar request to reinstate in-person dispensing requirements, seeking to allow the FDA more time for its safety review.
Read More: Australia May End Cervical Cancer by 2035, But Some Groups Need More Help
The ruling from the 5th Circuit Court of Appeals is seen as a notable victory for the anti-abortion movement in its efforts to restrict access to medication abortion. Critics of the decision, such as Skye Perryman, President and CEO of Democracy Forward, argue that it ignores scientific evidence and "puts women directly in harm’s way."
Background on Mifepristone Access
Since the COVID-19 pandemic, regulatory changes had permitted patients to obtain mifepristone through telehealth appointments and mail delivery, bypassing the need for in-person clinic visits. This accessibility was further facilitated by a 2023 regulation that removed the requirement for in-person dispensing. The current legal challenge specifically targets these eased regulations, seeking to revert to stricter dispensing protocols. The Supreme Court had previously ruled that anti-abortion doctors lacked the standing to challenge these regulations.
